Global Pulmonary Arterial Hypertension Market Report 2024

Pulmonary Arterial Hypertension Global Market Report 2024 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 200 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Pulmonary Arterial Hypertension Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Pulmonary Arterial Hypertension Market Definition And Segments

Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow.

The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/subcutaneous, and inhalational modes and distributed through retail and online channels.

The pulmonary arterial hypertension market covered in this report is segmented –

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators

2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational

3) By Distribution channel: Retail, Online

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $7.85 billion in 2023 to $8.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth

The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and the related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published by the National Organization for Rare Disorders, Inc., new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500–1000 new cases each year, and Europe is expected to have similar incidence rates.

Elevated Clinical Trials Activity Fuels Growth In The Pulmonary Arterial Hypertension Market

Th rising clinical trials for drug development is expected to propel the growth of the pulmonary arterial hypertension market going forward. Clinical trials for drug development are research studies conducted to evaluate the safety, efficacy, and potential side effects of a new drug or treatment in humans. Clinical trials for drug development of pulmonary arterial hypertension can lead to the development of new and more effective treatments, improving the quality of life, enhancing safety and efficacy, and early access, and helping identify cost-effective treatments. For instance, in May 2023, according to Xtalks, a Canada-based company specializing in providing life science webinars and virtual events, there are 452,604 clinical studies that have been registered on ClinicalTrials. gov as of May 17, 2023.64,838 studies out of the total number that have been registered are actively seeking participants which is an increase of 365,000 registered trials in 2021.Therefore, the rising clinical trials for drug development is driving the growth of the pulmonary arterial hypertension market.

Major companies operating in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

Innovative Technological Breakthroughs Transforming Pulmonary Arterial Hypertension Treatment Landscape

Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drug sector are focusing on developing new medicines to improve and cure these diseases. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease. Tyvaso is an inhalation solution that helps patients enhance their exercise abilities, reduce breathing difficulties, have a low tolerance for exertion, and have a higher mortality rate.

Increasing Focus On Product Approvals To Provide Reliable Services To Their Customers

Major companies operating in the pulmonary arterial hypertension market are focusing on product approvals such as tyvaso to drive revenues in their market. Tyvaso (treprostinil) inhalation solution is prescribed to treat patients with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary hypertension in order to enhance their capacity for activity. For instance, in April 2021, United Therapeutics Corporation, a US-based biotechnology company got FDA approval for tyvaso. Tyvaso is used for the treatment of pulmonary hypertension associated with interstitial lung disease. The FDA approved Tyvaso's supplementary new drug application (sNDA) for PH-ILD based on data from increase. Tyvaso's FDA approval for individuals with PH-ILD is a significant advance in treatment for this at-risk patient population.

Merck Group's Strategic Expansion Is Acquiring Acceleron Pharma's Rare Disease Therapies

In September 2021, Merck Group, a German-based multinational science and technology company that specializes in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication, and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.

North America was the largest region in the pulmonary arterial hypertension market in 2023.The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pulmonary Arterial Hypertension Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $8.57 billion
Revenue Forecast In 2033 $11.99 billion
Growth Rate CAGR of 8.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, Online
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled United Therapeutics Corporation; Acceleron Pharma Inc.; Actelion Pharmaceuticals US Inc.; Bayer AG; Eli Lilly and Company; Gilead Sciences Inc.; GlaxoSmithKline plc; Johnson & Johnson; Liquidia Technologies Inc.; Lupin Pharmaceuticals Inc.; Natco Pharma Ltd.; Pfizer Inc.; Sandoz AG; Teva Pharmaceutical Industries Ltd.; Zydus Pharmaceutical USA Inc.; Allegheny Health Network; Cedars-Sinai Medical Center; Cleveland Clinic; Houston Methodist Hospital; Johns Hopkins Medicine; Massachusetts General Hospital; Mayo Clinic; MedStar Heart & Vascular Institute; National Jewish Health; NewYork-Presbyterian Hospital; Ochsner Medical Center; Royal Brompton & Harefield NHS Foundation Trust; Rush University Medical Center; Stanford Health Care; Swedish Medical Center; Temple University Hospital; University of California Health.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Pulmonary Arterial Hypertension Market Characteristics

    3. Pulmonary Arterial Hypertension Market Trends And Strategies

    4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Pulmonary Arterial Hypertension Market Size and Growth

    5.1. Global Pulmonary Arterial Hypertension Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Pulmonary Arterial Hypertension Market Segmentation

    6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Endothelin Receptor Antagonists (ERAs)

    PDE-5 Inhibitors

    Prostacyclin and Prostacyclin Analogs

    SGC Stimulators

    6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral

    Intravenous/ subcutaneous

    Inhalational

    6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Retail

    Online

    7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

    7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Pulmonary Arterial Hypertension Market

    8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Pulmonary Arterial Hypertension Market

    9.1. China Pulmonary Arterial Hypertension Market Overview

    9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Pulmonary Arterial Hypertension Market

    10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Pulmonary Arterial Hypertension Market

    11.1. Japan Pulmonary Arterial Hypertension Market Overview

    11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Pulmonary Arterial Hypertension Market

    12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Pulmonary Arterial Hypertension Market

    13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Pulmonary Arterial Hypertension Market

    14.1. South Korea Pulmonary Arterial Hypertension Market Overview

    14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Pulmonary Arterial Hypertension Market

    15.1. Western Europe Pulmonary Arterial Hypertension Market Overview

    15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Pulmonary Arterial Hypertension Market

    16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Pulmonary Arterial Hypertension Market

    17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Pulmonary Arterial Hypertension Market

    18.5. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Pulmonary Arterial Hypertension Market

    19.9. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Pulmonary Arterial Hypertension Market

    20.13. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Pulmonary Arterial Hypertension Market

    21.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview

    21.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Pulmonary Arterial Hypertension Market

    22.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Pulmonary Arterial Hypertension Market

    23.1. North America Pulmonary Arterial Hypertension Market Overview

    23.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Pulmonary Arterial Hypertension Market

    24.1. USA Pulmonary Arterial Hypertension Market Overview

    24.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Pulmonary Arterial Hypertension Market

    25.1. Canada Pulmonary Arterial Hypertension Market Overview

    25.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Pulmonary Arterial Hypertension Market

    26.1. South America Pulmonary Arterial Hypertension Market Overview

    26.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Pulmonary Arterial Hypertension Market

    27.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Pulmonary Arterial Hypertension Market

    28.1. Middle East Pulmonary Arterial Hypertension Market Overview

    28.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Pulmonary Arterial Hypertension Market

    29.1. Africa Pulmonary Arterial Hypertension Market Overview

    29.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

    30.1. Pulmonary Arterial Hypertension Market Competitive Landscape

    30.2. Pulmonary Arterial Hypertension Market Company Profiles

    30.2.1. United Therapeutics Corporation

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Acceleron Pharma Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Actelion Pharmaceuticals US Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Bayer AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Eli Lilly and Company

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking

    32. Global Pulmonary Arterial Hypertension Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

    34. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis

    34.1 Pulmonary Arterial Hypertension Market In 2028 - Countries Offering Most New Opportunities

    34.2 Pulmonary Arterial Hypertension Market In 2028 - Segments Offering Most New Opportunities

    34.3 Pulmonary Arterial Hypertension Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: United Therapeutics Corporation Financial Performance
  • Table 75: Acceleron Pharma Inc. Financial Performance
  • Table 76: Actelion Pharmaceuticals US Inc. Financial Performance
  • Table 77: Bayer AG Financial Performance
  • Table 78: Eli Lilly and Company Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: United Therapeutics Corporation Financial Performance
  • Figure 75: Acceleron Pharma Inc. Financial Performance
  • Figure 76: Actelion Pharmaceuticals US Inc. Financial Performance
  • Figure 77: Bayer AG Financial Performance
  • Figure 78: Eli Lilly and Company Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Respiratory Devices And Equipment (Diagnostic) Global Market Report 2024 – By Product (Instruments And Devices, Assays And Reagents), By Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests), By Disease Type (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases), By End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Anti-Hypertensive Drugs Global Market Report 2024 – By Therapeutics (Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators), By Disease Source (Primary Hypertension, Secondary Hypertension), By End Users (Hospitals, Clinics, Homecare) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Anticoagulants Global Market Report 2024 – By Drug Class (Factor Xa Inhibitor, Heparin And LMWH, Vitamin K Antagonist, Other Drug Classes), By Route Of Administration (Oral Anticoagulant, Injectable Anticoagulant), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Venous Thromboembolism, Atrial Fibrillation Or Flutter, Coronary Artery Disease, Other Applications), By End User (Hospitals, Homecare, Specialty Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Cardiovascular Medical Lasers Global Market Report 2024 – By Type (Excimer Laser, Carbon Dioxide Laser), By Application (Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, Laser Angioplasty For Peripheral Arterial Diseases), By End Use (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Bioabsorbable Stents Global Market Report 2024 – By Product Type (Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents), By Absorption Rate (Slow- absorption stents, Fast- absorption Stents), By Applications (Coronary Artery Diseases, Peripheral Artery Diseases) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Transfusion Diagnostics Global Market Report 2024 – By Type (Instruments and Kits, Reagents, Other Types), By Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test), By Application (Blood Grouping, Disease Screening), By End User (Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Culture Tests Global Market Report 2024 – By Method (Conventional/Manual Methods, Automated Methods), By Product (Consumables, Instruments, Software and Services), By Technology (Culture-Based Technology, Molecular Technologies, Microarrays, PCR (Polymerase Chain Reaction), PNA-FiSH (Peptide Nucleic Acid – Fluorescent in Situ Hybridization), Proteomics Technology), By Application (Bacteremia, Fungemia, Mycobacterial Detection), By End User (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Laboratories) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Blood Collection Devices Global Market Report 2024 – By Type (Blood Collection Tubes, Lancet, Micro Container Tubes, Warming Devices), By Method (Manual Blood Collection, Automatic Blood Collection), By Material (Glass, Stainless Steel, Plastic), By End User (Hospitals, Blood Donation Centers, Diagnostic Center, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the pulmonary arterial hypertension market?

Pulmonary arterial hypertension refers to a form of excessive blood pressure that harms the right side of the heart and the arteries in the lungs. The lungs' artery walls become constricted and rigid due to this long-lasting, incurable condition. The pulmonary arterial hypertension drugs relax the muscles in the walls of the blood vessels, increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels that causes them to narrow. For further insights on the rail asset management market, request a sample here

How will the pulmonary arterial hypertension market drivers and restraints affect the pulmonary arterial hypertension market dynamics? What forces will shape the pulmonary arterial hypertension industry going forward?

The pulmonary arterial hypertension market major growth driver - elevated prevalence of pulmonary arterial hypertension (pah) driving market growth. For further insights on the rail asset management market, request a sample here

What is the forecast market size or the forecast market value of the pulmonary arterial hypertension market ?

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $7.85 billion in 2023 to $8.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (pah), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension. The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of pah drugs and therapies, integration of precision medicine in pah treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy. For further insights on the rail asset management market, request a sample here

How is the pulmonary arterial hypertension market segmented?

The pulmonary arterial hypertension market is segmentedThe pulmonary arterial hypertension market covered in this report is segmented –
1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
3) By Distribution channel: Retail, OnlineFor further insights on the rail asset management market, request a sample here

Which region has the largest share of the pulmonary arterial hypertension market? What are the other regions covered in the report?

North America was the largest region in the pulmonary arterial hypertension market in 2023. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the rail asset management market, request a sample here.

Who are the major players in the pulmonary arterial hypertension market?

Major companies operating in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health. For further insights on the rail asset management market, request a sample here.

What are the key trends in the pulmonary arterial hypertension market?

Major trend in the pulmonary arterial hypertension market - innovative technological breakthroughs transforming pulmonary arterial hypertension treatment landscape. For further insights on the rail asset management market, request a sample here.

What are the major opportunities in the pulmonary arterial hypertension market? What are the strategies for the pulmonary arterial hypertension market?

For detailed insights on the major opportunities and strategies in the pulmonary arterial hypertension market, request a sample here.

How does the pulmonary arterial hypertension market relate to the overall economy and other similar markets?

For detailed insights on pulmonary arterial hypertension market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the pulmonary arterial hypertension industry?

For detailed insights on the mergers and acquisitions in the pulmonary arterial hypertension industry, request a sample here.

What are the key dynamics influencing the pulmonary arterial hypertension market growth? SWOT analysis of the pulmonary arterial hypertension market.

For detailed insights on the key dynamics influencing the pulmonary arterial hypertension market growth and SWOT analysis of the pulmonary arterial hypertension industry, request a sample here.